about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsVaccine adjuvants as potential cancer immunotherapeuticsPathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyImmune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsIL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy ResistanceDelivery of host cell-directed therapeutics for intracellular pathogen clearanceFractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour ResponseThe Role of Toll-Like Receptors in Hematopoietic MalignanciesHarnessing the Microbiome to Enhance Cancer ImmunotherapyPerioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects.The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation.Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumorsBig opportunities for small molecules in immuno-oncology.Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.Targeting the tumor microenvironment to enhance antitumor immune responsesThe stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy.Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies.TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.Baicalin Protects Keratinocytes from Toll-like Receptor-4 Mediated DNA Damage and Inflammation Following Ultraviolet Irradiation.Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4.Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.The Combination of MBP and BCG-Induced Dendritic Cell Maturation through TLR2/TLR4 Promotes Th1 Activation In Vitro and Vivo.All-Trans Retinoic Acid Modulates TLR4/NF-κB Signaling Pathway Targeting TNF-α and Nitric Oxide Synthase 2 Expression in Colonic Mucosa during Ulcerative Colitis and Colitis Associated CancerGranzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Combination cancer immunotherapies tailored to the tumour microenvironment.Pattern recognition receptors: immune targets to enhance cancer immunotherapy.Modifying the tumor microenvironment using nanoparticle therapeuticsGenomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.Coley's Lessons Remembered: Augmenting Mistletoe Therapy.Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia.Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Toll-like receptor 7 involves the injury in acute kidney ischemia/reperfusion of STZ-induced diabetic rats.
P2860
Q26741260-030C83EC-A325-49AA-A7EC-1E344E556180Q26752522-5773EE55-96F4-4102-B5FD-2E59559014ABQ26765345-7161099B-FB7E-448D-8699-84A81A5293CDQ26782566-7BBF96FD-CB18-4FAE-8205-860753DF6D14Q26784480-B7F7D9D1-FDE9-4BE7-BF19-223F8F127B96Q26866390-B64D9CC5-CFA7-4E5D-8A22-42D01AACA175Q27006858-3D6B844B-2E6D-4F87-BA0B-31C132BECDF8Q27334088-11BB34C8-2A5D-4E10-B9F6-69FFC1D2932EQ28077740-6EAB4FAA-1631-4F4D-AFAE-69DB5C5012BEQ28088598-78263120-5A7E-4AEA-8C4B-099687AAA16AQ30700261-E0879F65-21B4-49E8-BA90-D051D394BCB3Q33648709-5F954A78-FBFB-4D9F-B5C4-FACCC5F77F14Q33786891-0C86430C-6131-41FC-A939-C406EC542275Q33824623-FF912524-0314-4FCF-AF67-D2C124017B00Q34487689-45095D9B-0734-4AF8-9D99-DB4B85EA57A2Q34750515-A3BF04F4-510A-4861-82A3-D54A205BCCF7Q35176307-F30644E5-A210-470C-8853-7FDAA82CEF24Q35189391-E7468249-E01E-4C80-92BD-A4E69F99DA76Q35285757-D964C43F-7DA5-45E8-A3FB-1C0CEF9425C8Q35612358-F9C2D5F0-6DCB-463A-B499-B1EC2FC619B8Q35746351-26BBFE86-0F15-4BF6-B3A3-DF21811532E8Q36244769-A0319484-EF10-4B8E-855A-C9623AF5B39FQ36247376-97DC1A1A-A118-4AE3-872D-60612ABF1886Q36779686-4E9D30CE-F2D6-4919-903A-B10522377C07Q36821236-A6F5B617-2113-4C88-B708-4D608E2AEE96Q37029731-D929A244-5860-4799-9994-DFED530F0C3EQ37672847-069B1B87-BA6E-4F43-B43F-D583292EA1CCQ37734382-23F971E7-332A-4D22-ABF3-B4239C1FFECBQ38301125-F869A6B5-DB09-49AA-A6A7-40A6CE29033EQ38571471-11266BB2-E985-453F-8857-2AB0707D8890Q38645178-3691259C-11A4-4C68-AFC4-A8EFF9D70080Q38690773-F7DAC09C-488F-4DBF-BBF8-5147FEA7C780Q38796320-7CF66EF6-6C4D-4165-B9CB-8F8CAD1D7455Q38835169-5571A89E-9EA3-4348-95D3-1B6F354B5456Q38840254-C89B36A6-0C7C-451D-8732-D27499EF470DQ38888128-CE97A1CB-75A5-42AE-905D-7AAF6A76E224Q38912287-A5360608-A59B-432B-9F1D-A8E7B5343E16Q38971847-D8DA8736-7EBF-4091-A916-4128C067E7A7Q39267549-10114A93-A2FD-4B5C-A4CE-6EE70A3BA102Q39529337-2607B968-0873-433D-BE20-1541389413CF
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
TLR agonists: our best frenemy in cancer immunotherapy
@en
type
label
TLR agonists: our best frenemy in cancer immunotherapy
@en
prefLabel
TLR agonists: our best frenemy in cancer immunotherapy
@en
P2093
P2860
P356
P1476
TLR agonists: our best frenemy in cancer immunotherapy
@en
P2093
Ann Mary Joseph
Eduardo Davila
Sabina Kaczanowska
P2860
P304
P356
10.1189/JLB.1012501
P577
2013-03-08T00:00:00Z